Kura Oncology
KURA
174 hedge funds and large institutions have $1.66B invested in Kura Oncology in 2024 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 55 increasing their positions, 61 reducing their positions, and 19 closing their positions.
139% more call options, than puts
Call options by funds: $3.13M | Put options by funds: $1.3M
53% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 19
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
5% more funds holding
Funds holding: 165 → 174 (+9)
0.41% less ownership
Funds ownership: 106.06% → 105.66% (-0.41%)
4% less capital invested
Capital invested by funds: $1.72B → $1.66B (-$64.8M)
10% less repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 61
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
+$28.9M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$20.4M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$11.9M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$7.91M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$6.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$27M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$14.5M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$11.3M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$9.64M |
| 5 |
PM
Prosight Management
Dallas,
Texas
|
-$6.79M |
KURA Hedge Fund Activity: Q2 2024 in Review
174 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Kura Oncology (KURA) for Q2 2024, worth a combined $1.66B — down 3.8% from $1.72B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new KURA positions and 19 closed out — a net gain of 10 holders — while 55 added to existing stakes and 61 trimmed.
The largest buyer was Paradigm Biocapital Advisors, adding an estimated $28.9M. The largest seller was State Street, cutting an estimated $27M.
- 174 institutional investors held Kura Oncology (KURA) as of Q2 2024, up from 165 in Q1 2024.
- Funds reported $1.66B of Kura Oncology stock for Q2 2024, down 3.8% quarter-over-quarter.
- 29 funds opened new Kura Oncology positions in Q2 2024 and 19 closed out, a net change of +10 holders.
- The largest Kura Oncology buyer in Q2 2024 was Paradigm Biocapital Advisors, an estimated $28.9M added.
- The largest Kura Oncology seller in Q2 2024 was State Street, an estimated $27M sold.
Based on aggregated 13F filings for Q2 2024.